Protein from concentrated conditioned media and that from cell extracts was immunoblotted for SOSTDC1. with recombinant SOSTDC1 or Wise, a SOSTDC1 orthologue, exhibited that SOSTDC1 selectively blocks BMP-7-induced Smad phosphorylation without diminishing BMP-2 or Wnt3a-induced signaling. In conclusion, SOSTDC1 mRNA and protein are reduced in breast cancer. High SOSTDC1 mRNA levels correlate with increased distant metastasis-free survival in breast cancer patients. SOSTDC1 differentially affects Wnt3a, BMP-2, and BMP-7 signaling in breast cancer cells. These results identify SOSTDC1 as a clinically important extracellular regulator of multiple signaling pathways in breast cancer. Keywords:Beta-catenin (BMP), Bone morphogenetic protein(BMP), Breast cancer, Sclerostin domain made up of 1 (SOSTDC1), Wingless/int (Wnt), Wise == Introduction == Despite significant advances in prevention, diagnosis, and treatment, breast cancer remains the second most deadly cancer in women in the United States [1]. Treatment of breast cancer is complicated by the distinct subtypes that exist, each with a unique disease course and optimal treatment mode [24]. These disparities highlight 5,15-Diacetyl-3-benzoyllathyrol the need for new therapeutic and diagnostic targets for breast cancer. Potential sources for such targets are the molecular signaling pathways commonly 5,15-Diacetyl-3-benzoyllathyrol disrupted in cancer cells [59], especially those that regulate cancer-relevant cellular functions such as cell cycle progression, cellular proliferation, and cell death. Sclerostin domain made up of 1 protein (SOSTDC1) is a critical regulator of cell signaling, participating in processes from development to cancer. Highly conserved within vertebrates, orthologues of SOSTDC1 have been identified in species fromXenopusto humans [10]. SOSTDC1 has been implicated in a range of normal processes including developmental patterning [11], tooth development [12], hair growth [13], and reproduction [14]. SOSTDC1 also impacts disease processes such as renal injury [15], adult renal cancer [16], and 5,15-Diacetyl-3-benzoyllathyrol pediatric Wilms tumors, where its gene has been identified as a candidate tumor suppressor gene [17]. One way that SOSTDC1 affects these diverse processes by regulating the activity of bone morphogenetic proteins (BMPs, [18,19]). BMPs are ligands that activate pathways involved in cell proliferation and differentiation. Binding of BMP proteins to BMP receptors leads to receptor phosphorylation [20,21]. Phosphorylated BMP receptors recruit and phosphorylate receptor-regulated Smad proteins, Smad-1, -5, and -8. Phosphorylated receptor Smads associate with Smad-4, which permits nuclear translocation of the Smad complex. In the nucleus, this complex induces the transcription of cell regulatory factors includingp53, p21, andBcl-2-associated X(bax; reviewed in [22,23]). SOSTDC1 inhibits BMP signaling by binding directly to select BMP proteins including BMP-2, -4, and -7 [24]. This binding blocks the conversation of BMPs with their receptors, thus limiting BMP activity. SOSTDC1 can also regulate the wingless/int (Wnt) signaling pathway. Activation of the Wnt signaling pathway centers around the inactivation of an inhibitory complex that includes Axin, adenomatous polyposis coli protein (APC), and beta-catenin. Prior to Wnt pathway activation, the protein kinases Glycogen Synthase Kinase-3 (GSK-3) and casein kinase 1 gamma (CK1gamma) promote the phosphorylation of beta-catenin and APC. These phosphorylation events target beta-catenin for ubiquitination and proteosomal degradation. Transition to the active state is usually induced by the binding of a Wnt ligand to the Frizzled (Fzd) and low density lipoprotein receptor-related protein (LRP) receptor complex, promoting phosphorylation of LRP and other signaling Rabbit Polyclonal to MRPL2 proteins. Phosphorylated LRP can then associate with Axin, releasing beta-catenin from the inhibitory complex. Dissociation of beta-catenin prevents its phosphorylation, ubiquitination, and degradation. Stabilized beta-catenin then transits to the nucleus where it promotes transcription of Wnt pathway targets (reviewed in [25]). These targets are situation dependent, varying between cell types and activation contexts. Two cancer-relevant targets include c-Myc and cyclin D1 [2628]. SOSTDC1 can either enhance or inhibit Wnt signaling. For example, SOSTDC1 decreases Wnt signaling by impeding the binding of Wnt8 to 5,15-Diacetyl-3-benzoyllathyrol the LRP6 receptor [11]. The localization of SOSTDC1 also affects its activity: secreted SOSTDC1 can have either inhibitory or activating effects, but SOSTDC1 within the endoplasmic reticulum (ER) is usually exclusively inhibitory [29]..